BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25724425)

  • 1. Combining intraoperative carmustine wafers and Stupp regimen in multimodal first-line treatment of primary glioblastomas.
    Pavlov V; Page P; Abi-Lahoud G; Nataf F; Dezamis E; Robin A; Varlet P; Turak B; Dhermain F; Domont J; Louvel G; Souillard-Scemama R; Parraga E; Meder JF; Chrétien F; Devaux B; Pallud J
    Br J Neurosurg; 2015; 29(4):524-31. PubMed ID: 25724425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extent of resection and Carmustine wafer implantation safely improve survival in patients with a newly diagnosed glioblastoma: a single center experience of the current practice.
    Roux A; Peeters S; Zanello M; Bou Nassif R; Abi Lahoud G; Dezamis E; Parraga E; Lechapt-Zalcmann E; Dhermain F; Dumont S; Louvel G; Chretien F; Sauvageon X; Devaux B; Oppenheim C; Pallud J
    J Neurooncol; 2017 Oct; 135(1):83-92. PubMed ID: 28669011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
    Affronti ML; Heery CR; Herndon JE; Rich JN; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Bigner DD; Friedman HS
    Cancer; 2009 Aug; 115(15):3501-11. PubMed ID: 19514083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.
    Pallud J; Audureau E; Noel G; Corns R; Lechapt-Zalcman E; Duntze J; Pavlov V; Guyotat J; Hieu PD; Le Reste PJ; Faillot T; Litre CF; Desse N; Petit A; Emery E; Voirin J; Peltier J; Caire F; Vignes JR; Barat JL; Langlois O; Dezamis E; Parraga E; Zanello M; Nader E; Lefranc M; Bauchet L; Devaux B; Menei P; Metellus P;
    Neuro Oncol; 2015 Dec; 17(12):1609-19. PubMed ID: 26185110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis.
    Salvati M; D'elia A; Frati A; Brogna C; Santoro A; Delfini R
    J Neurosurg Sci; 2011 Mar; 55(1):1-6. PubMed ID: 21464805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carmustine wafer implantation for supratentorial glioblastomas, IDH-wildtype in "extreme" neurosurgical conditions.
    Roux A; Aboubakr O; Elia A; Moiraghi A; Benevello C; Fathallah H; Parraga E; Oppenheim C; Chretien F; Dezamis E; Zanello M; Pallud J
    Neurosurg Rev; 2023 Jun; 46(1):140. PubMed ID: 37329341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of the NICE Technology Appraisal 121 (gliadel and temozolomide) on survival in high-grade glioma.
    Barr JG; Grundy PL
    Br J Neurosurg; 2012 Dec; 26(6):818-22. PubMed ID: 22715955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymeric drug delivery for the treatment of glioblastoma.
    Wait SD; Prabhu RS; Burri SH; Atkins TG; Asher AL
    Neuro Oncol; 2015 Mar; 17 Suppl 2(Suppl 2):ii9-ii23. PubMed ID: 25746091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiRNA-181d Expression Significantly Affects Treatment Responses to Carmustine Wafer Implantation.
    Sippl C; Ketter R; Bohr L; Kim YJ; List M; Oertel J; Urbschat S
    Neurosurgery; 2019 Jul; 85(1):147-155. PubMed ID: 29846701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.
    Samis Zella MA; Wallocha M; Slotty PJ; Isik G; Hänggi D; Schroeteler J; Ewelt C; Steiger HJ; Sabel M
    Acta Neurochir (Wien); 2014 Feb; 156(2):313-23. PubMed ID: 24287680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases.
    Duntze J; Litré CF; Eap C; Théret E; Debreuve A; Jovenin N; Lechapt-Zalcman E; Metellus P; Colin P; Guillamo JS; Emery E; Menei P; Rousseaux P; Peruzzi P
    Ann Surg Oncol; 2013 Jun; 20(6):2065-72. PubMed ID: 23212763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
    Catalán-Uribarrena G; Bilbao-Barandica G; Pomposo-Gaztelu I; Undabeitia-Huertas J; Ruiz de Gopegui-Ruiz E; Galbarriatu-Gutiérrez L; Canales-Llantada M; Aurrecoechea-Obieta J; Igartua-Azkune A; Carbayo-Lozano G
    Acta Neurochir (Wien); 2012 Feb; 154(2):211-22; discussion 222. PubMed ID: 22002506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of surgical site infection in 401 consecutive patients with glioblastoma with and without carmustine wafer implantation.
    Chaichana KL; Kone L; Bettegowda C; Weingart JD; Olivi A; Lim M; Quinones-Hinojosa A; Gallia GL; Brem H
    Neurol Res; 2015 Aug; 37(8):717-26. PubMed ID: 25916669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival.
    Chaichana KL; Zaidi H; Pendleton C; McGirt MJ; Grossman R; Weingart JD; Olivi A; Quiñones-Hinojosa A; Brem H
    Neurol Res; 2011 Sep; 33(7):759-64. PubMed ID: 21756557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up.
    Della Puppa A; Lombardi G; Rossetto M; Rustemi O; Berti F; Cecchin D; Gardiman MP; Rolma G; Persano L; Zagonel V; Scienza R
    J Neurooncol; 2017 Jan; 131(2):331-340. PubMed ID: 27757721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance and accuracy of intraoperative frozen section diagnosis of the resection margin for effective carmustine wafer implantation.
    Asano K; Kurose A; Kamataki A; Kato N; Ogawa K; Katayama K; Kakuta K; Fumoto T; Ohkuma H
    Brain Tumor Pathol; 2018 Jul; 35(3):131-140. PubMed ID: 29948295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does high-dose carmustine increase overall survival in supratentorial high-grade malignant glioma? An EBMT retrospective study.
    Bay JO; Linassier C; Biron P; Durando X; Verrelle P; Kwiatkowski F; Rosti G; Demirer T;
    Int J Cancer; 2007 Apr; 120(8):1782-6. PubMed ID: 17230505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme.
    Darakchiev BJ; Albright RE; Breneman JC; Warnick RE
    J Neurosurg; 2008 Feb; 108(2):236-42. PubMed ID: 18240917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.
    Durando X; Lemaire JJ; Tortochaux J; Van-Praagh I; Kwiatkowski F; Vincent C; Bailly C; Verrelle P; Irthum B; Chazal J; Bay JO
    Bone Marrow Transplant; 2003 Apr; 31(7):559-64. PubMed ID: 12692621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of carmustine wafers in the treatment of glioblastoma multiforme: a systematic review.
    Zhang YD; Dai RY; Chen Z; Zhang YH; He XZ; Zhou J
    Turk Neurosurg; 2014; 24(5):639-45. PubMed ID: 25269031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.